scispace - formally typeset
P

Peter Vreken

Researcher at University of Amsterdam

Publications -  71
Citations -  4525

Peter Vreken is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Dihydropyrimidine dehydrogenase deficiency & Peroxisome. The author has an hindex of 30, co-authored 71 publications receiving 4309 citations.

Papers
More filters
Journal Article

Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.

TL;DR: This study demonstrated that in 59% of the cases, a decreased DPD activity could be detected in peripheral blood mononuclear cells and demonstrated that at least 57% (8 of 14) of the patients with a reduced D PD activity have a molecular basis for their deficient phenotype.
Journal ArticleDOI

Defective Remodeling of Cardiolipin and Phosphatidylglycerol in Barth Syndrome

TL;DR: Evidence is presented that patients with the rare disorder X-linked cardioskeletal myopathy and neutropenia (Barth syndrome, MIM 302060) have a primary defect in CL and PG remodeling, and an essential factor in this important cellular process is identified for the first time.
Journal ArticleDOI

Mutations in the 3β-Hydroxysterol Δ24-Reductase Gene Cause Desmosterolosis, an Autosomal Recessive Disorder of Cholesterol Biosynthesis

TL;DR: The data demonstrate that desmosterolosis is a cholesterol-biosynthesis disorder caused by mutations in DHCR24, a recently defined family of flavin adenine dinucleotide (FAD)–dependent oxidoreductases.
Journal ArticleDOI

Peroxisomal fatty acid alpha- and beta-oxidation in humans: enzymology, peroxisomal metabolite transporters and peroxisomal diseases.

TL;DR: The current state of knowledge about peroxisomal fatty acid α- and β-oxidation is described with particular emphasis on the enzymology of the β- and α-oxidized substrates and the interaction with other subcellular compartments.
Journal ArticleDOI

Smith-Lemli-Opitz syndrome is caused by mutations in the 7-dehydrocholesterol reductase gene.

TL;DR: Data demonstrate that Smith-Lemli-Opitz syndrome is caused by mutations in the gene coding for 7-dehydrocholesterol reductase, which catalyzes the final step in the cholesterol-biosynthesis pathway.